TELO SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 17, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment

Oct 6, 2026

8-K

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AM

Sep 17, 2026

8-K

Telomir Pharmaceuticals Announces Voting Results from 2026 Annual Meeting of Stockholders

Sep 16, 2026

8-K

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

Sep 14, 2026

8-K

Telomir Pharmaceuticals Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

Aug 10, 2026

8-K

Telomir Pharmaceuticals Announces Peer-Reviewed Publication Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn

Jun 15, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Offering amount: $5,600,000 | Shares: 5,292,810 | Bank: Alexander Capital, L.P.

Nov 5, 2026

424B4

6,203,696 Shares

Feb 12, 2024

424B1

OFFERING | Shares amount: 1,000,000 | Share price: $7.00 | Offering amount: $7,000,000.00

Feb 12, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION EFFECTIVE, DATED 2026-11-05

Oct 27, 2026

S-3

Form S-3 - Registration statement under Securities Act of 1933

Feb 14, 2025

8-A12B

Registration

Feb 6, 2024

S-1/A

INITIAL REGISTRATION FOR OFFERING | Shares amount: 1,000,000 | Share price: $7.00 | Offering amount: $7,000,000.00 EFFECTIVE

Jan 3, 2024

S-1/A

INITIAL REGISTRATION FOR OFFERING EFFECTIVE

Dec 19, 2023

S-1/A

INITIAL REGISTRATION FOR OFFERING | Shares amount: 1,000,000 | Share price: $7.00 | Offering amount: $7,000,000.00 EFFECTIVE

Dec 14, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Aug 19, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 28, 2026

DEFM14A

Form DEFM14A - Definitive proxy statement relating to merger or acquisition

Feb 19, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Feb 19, 2026

PRER14A

Form PRER14A - Preliminary Proxy Soliciting materials

Feb 4, 2026

PRER14A

Form PRER14A - Preliminary Proxy Soliciting materials

Jan 23, 2026

Ownerships

TYPE

HEADLINE

FILED AT

S-3

Form S-3 - Registration statement under Securities Act of 1933

Oct 27, 2026

SCHEDULE 13G/A

DEJORIA JOHN PAUL (Filed by)

Aug 14, 2026

Whalen Matthew Pratt (Reporting)

Jul 27, 2026

MacPherson Edward Clouston (Reporting)

Jul 27, 2026

Del Giudice Matthew Paul (Reporting)

Jul 27, 2026

Mushak Andriy (Reporting)

Jun 9, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 6, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 3, 2025

CORRESP

Form CORRESP - Correspondence

Feb 26, 2025

LETTER

Form UPLOAD - SEC-generated letter

Feb 20, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Feb 9, 2024

CORRESP

Form CORRESP - Correspondence

Feb 6, 2024

Telomir Pharmaceuticals, Inc. Common Stock TELO · SEC Filings